News Otsuka Holdings Co., Ltd.

Equities

4578

JP3188220002

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-19 am EDT			5-day change	1st Jan Change
6,186 ^JPY	-0.13%		-3.13%	+16.96%

Apr. 09	H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	MT
Mar. 29	Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	Apr. 09	MT
Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation	Mar. 29	MT
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	Mar. 27	MT
Jefferies Adjusts Otsuka Holdings’ Price Target to 7,400 Yen From 6,800 Yen, Keeps at Buy	Mar. 18	MT
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical	Mar. 17	MT
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors	Mar. 06	CI
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka	Feb. 26	DJ
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses	Feb. 16	MT
Otsuka Holdings Co., Ltd. Provides Year-End Dividend Guidance for the Fiscal Year Ending December 31, 2024	Feb. 16	CI
Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending December 31, 2024	Feb. 16	CI
Otsuka Holdings Co., Ltd. Announces Year-End Dividend for the Year Ended December 31, 2023, Payable on March 29 , 2024; Provides Second Quarter-End Dividend Guidance for the Fiscal Year 2024	Feb. 13	CI
Otsuka Holdings Lowers 2023 Profit Outlook	Feb. 13	MT
Japan's Nikkei cruises to 34-year peak, briefly breaching 38,000 range	Feb. 13	RE
Japan's Nikkei soars to 34-year high on chip shares, earnings	Feb. 12	RE
Phase 3 Trial for Otsuka's Alzheimer's-related Agitation Treatment Fails to Meet Primary Endpoint	Feb. 12	MT
Otsuka's drug for Alzheimer's disease agitation fails in late stage study	Feb. 12	RE
Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ended December 31, 2023	Feb. 12	CI
Otsuka Group Selected for CDP Climate Change a List for a Second Consecutive Year	Feb. 08	AQ
Ionis Pharmaceuticals Says Potential Angioedema Treatment Met Primary Endpoint of Phase 3 Study	Jan. 22	MT
Otsuka Holdings Co., Ltd. - Donations to Support Relief Efforts Following the Noto Peninsula Earthquake	Jan. 10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Otsuka Holdings Co., Ltd.

Equities

4578

JP3188220002

Summary

Filters